News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

March

10

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force...

12

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record...

9

Exagen and Queen Mary University of London Announce Exclusive License and Collaboration Agreement

Collaboration to develop novel patented molecular signatures for rheumatoid arthritis biologic therapeutic selection SAN...

10

Exagen Inc. Reports Third Quarter 2020 Results

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing...

12

Exagen Inc. Reports Third Quarter 2019 Results

AVISE® Testing Revenue Drives 27% Revenue Growth SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq:...

Recent developments